Cargando…
Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404
Severe acute respiratory syndrome coronaviruses 1 and 2 (SARS-CoV-1 and SARS-CoV-2) pose a threat to global public health. The 3C-like main protease (M(pro)), which presents structural similarity with the active site domain of enterovirus 3C protease, is one of the best-characterized drug targets of...
Autores principales: | Fàbrega-Ferrer, Montserrat, Herrera-Morandé, Alejandra, Muriel-Goñi, Sara, Pérez-Saavedra, Julia, Bueno, Paula, Castro, Victoria, Garaigorta, Urtzi, Gastaminza, Pablo, Coll, Miquel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632241/ https://www.ncbi.nlm.nih.gov/pubmed/36336176 http://dx.doi.org/10.1016/j.antiviral.2022.105458 |
Ejemplares similares
-
SARS-CoV-2 Fears Green: The Chlorophyll Catabolite Pheophorbide A Is a Potent Antiviral
por: Jimenez-Aleman, Guillermo H., et al.
Publicado: (2021) -
Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
por: Ginex, Tiziana, et al.
Publicado: (2021) -
Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target
por: García-Dorival, Isabel, et al.
Publicado: (2021) -
COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
por: García-Arriaza, Juan, et al.
Publicado: (2021) -
Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron
por: Casasnovas, José M., et al.
Publicado: (2022)